Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Zhiyue Rao, Jian Fang et al.|Nature Medicine|2025Cited by 30
IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in gliomaXueqin Chen, Haipeng Zhang, Hao Duan et al.|Nature Communications|2023Cited by 26
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort studyDongming Zhang, Mengzhao Wang, Xiaoyan Liu et al.|Translational Lung Cancer Research|2023Cited by 20